Tumor Immunology group
The Tumor Immunology group investigates the interplay between the immune system and cancer with a main focus on two types of immune cells, namely tumor-specific T cells and macrophages.
The immune system has a central role in cancer because it can both promote and suppress tumor development. Our research vision is to increase our understanding of how the immune system naturally fights cancer in order to develop novel strategies for cancer immunotherapy in humans. We perform both in vivo and in vitro experiments with experimental mouse models, various cell lines, and tumor tissue from patients with non-small cell lung cancer (NSCLC). On the basis of our previous findings, we focus our research on the mechanisms whereby tumor-specific T helper cells and macrophages collaborate to recognize and eliminate malignant cells. We are also very interested in cytokine-mediated communication between immune cells and in tumor-associated inflammation.
- Macrophage activation and killing of tumor cells
- Cancer-suppressive versus cancer-promoting inflammation
- Immune cell composition in human non-small cell lung cancer
- Prognostic value of tumor-infiltrating immune cells in lung cancer
- A novel vaccine strategy against cancer and infectious diseases
Alexandre Corthay, PhD
Head of Tumor immunology group
President of the Norwegian Society for Immunology
Mail address: Department of Pathology, Oslo University Hospital Rikshospitalet, P.O. Box 4950 Nydalen, NO-0424 Oslo, Norway.
Visitor address: Institute of Pathology, Oslo University Hospital Rikshospitalet, Sognsvannsveien 20, Oslo, Norway. Office: room A3.M018.
Growth coordination during development
Mar 27, 2017
Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology
Mar 15, 2017
Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research
Mar 7, 2017
Immunological Tolerance. Part I of a Report of a Workshop on Foundational Concepts of Immune Regulation
Scand J Immunol, 85 (2), 84-94
Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
Cancer Res, 76 (23), 6864-6876